Caribou Biosciences, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Caribou Biosciences, Inc. (CRBU) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $1.63 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-11-06
- Caribou Biosciences, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-09-30 was $0.00.
- Caribou Biosciences, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-06-30 was $125.00K.
- Caribou Biosciences, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-03-31 was $1.50M.
- Caribou Biosciences, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-09-30 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $125.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.63M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.63M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $1.50M 10-Q · filed 2024-05-07 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $300.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |